Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacture and commercialisation of endomicroscopic digital imaging technology solutions
A money trail is forming behind @Optiscan technology-based mission to tackle the scourge of #cancer, with revenue starting to stream into the company’s coffers from the lucrative Chinese health sector.
$OIL #BULLSNBEARSWA#ASX#MedTech@westaustralian
https://t.co/dSly21TfQe
Optiscan has developed a hand-held pen-like device for digital biopsies that harnesses confocal laser endo-microscopy to produce hi-res images. | #health#stocks#biotech#medicine#ASX https://t.co/39jOaJ203L
Delighted to be collaborating with Design + Industry in developing our new product portfolio. With 260 industry awards over 35 years, we look forward to perfecting our new devices for clinicians, health systems and patients.
#imaginethepossibilities#digitalpathology
Optiscan Imaging Ltd wishes all our US colleagues, clinicians, partners, friends, and their families a wonderful #Thanksgiving.
We hope your day is filled with warmth, happiness, and the company of those closest to you.
Optiscan Imaging Ltd has released its Quarterly Report and Appendix 4C for the quarter ended 30 September 2023.
Read: https://t.co/N5bshE8ZmX
#optiscanimaging#asx
Delighted to welcome Brendan Fafiani as our new Chief Operating Officer. Mr Fafiani will lead operations at our Melbourne headquarters, our operational planning, commercialisation strategy, customer and development efforts.
Read: https://t.co/N5bshE8ZmX
#optiscanimaging#ASX
Delighted to announce the appointment of Tim Rowe and Shayra Leon as our new Business Development Managers for North America.
Read: https://t.co/N5bshE8ZmX
#asx#optiscanimaging
Pleased to announce interim readout on our Breast Cancer Intraoperative Assessment Study, revealing excellent correlation between our real-time #CLE imaging and traditional histological analysis.
Read more: https://t.co/4naYd0K6Nj
#optiscanimaging#digitalpathology#asx
Optiscan Imaging has rounded out a dynamic year with a whopping 66 per cent revenue boost to nearly $1.7 million following the sale of its ViewnVivo research device to an American pharmaceutical company. #BULLSNBEARSWA https://t.co/kJxhsJK7jJ
#Medtech company @Optiscan_ has rounded out a dynamic year with a whopping 66 per cent revenue boost to nearly $1.7 million following the sale of its #ViewnVivo research device to an American pharmaceutical company.
$OIL @westaustralian@prolucid
https://t.co/wVAIZHR8dq
We have released our Annual Report FY23, with revenues increasing to $1.68m (+66%) and net cash outflows decreasing from $3.8m to $3.2m. We thank all our collaborators, shareholders, and employees for their ongoing support & look forward to FY24.
https://t.co/N5bshE8ZmX